Levels of indoxyl sulfate in kidney transplant patients, and the relationship with hard outcomes

Circulation Journal

Volumn 80, Issue 3, 2016, Pages 722-730

  Liabeuf, Sophie ^a   Desjardins, Lucie ^a   Massy, Ziad A ^b   Brazier, François ^c   Westeel, Pierre François ^c   Mazouz, Hakim ^c   Titeca Beauport, Dimitri ^c   Diouf, Momar ^c   Glorieux, Griet ^d   Vanholder, Raymond ^d   Jaureguy, Maité ^c   Choukroun, Gabriel ^a,c  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Indoxyl sulfate; Mortality; Outcomes; Renal transplantation; Uremic toxin

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; HEMOGLOBIN; INDICAN; PHOSPHATE; UREMIC TOXIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; AGED; BLOOD; FOLLOW UP; GRAFT REJECTION; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; INDICAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84959036223     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0949     Document Type: Article

References (28)

1. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C, et al. US renal data system 2012: Annual data report. Am J Kidney Dis 2013; 61: A7, e1-e476, doi:10.1053/j.ajkd.2012.11.031.
2. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Neprol Dial Transplant 2005; 20: 1048-1056.
3. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
4. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
5. Lekawanvijit S. Role of gut-derived protein-bound uremic toxins in cardiorenal syndrome and potential treatment modalities. Circ J 2015; 79: 2088-2097.
6. Yamazaki H, Yamaguchi K, Soeki T, Wakatsuki T, Niki T, Taketani Y, et al. Impact of indoxyl sulfate, a uremic toxin, on non-culprit coronary plaque composition assessed on integrated backscatter intravascular ultrasound. Circ J 2015; 79: 1773-1779.
7. Yoshikawa D, Ishii H, Suzuki S, Takeshita K, Kumagai S, Hayashi M, et al. Plasma indoxyl sulfate and estimated glomerular filtration rate. Circ J 2014; 78: 2477-2482.
8. Liabeuf S, Neirynck N, Drueke TB, Vanholder R, Massy ZA. Clinical studies and chronic kidney disease: What did we learn recently? Semin Nephrol 2014; 34: 164-179.
9. Claes KJ, Bammens B, Kuypers DR, Meijers B, Naesens M, Sprangers B, et al. Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. Neprol Dial Transplant 2014; 29: 1965-1972.
10. Massy ZA. Cardiovascular risk factors in kidney transplantation. Curr Opin Urol 2001; 11: 139-142.
11. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review. J Am Soc Nephrol 2014; 25: 1897-1907.
12. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. P-cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Neprol Dial Transplant 2011; 26: 938-947.
13. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558.
14. Melamed ML, Plantinga L, Shafi T, Parekh R, Meyer TW, Hostetter THE, et al. Retained organic solutes, patient characteristics and allcause and cardiovascular mortality in hemodialysis: Results from the retained organic solutes and clinical outcomes (rosco) investigators. BMC Nephrol 2013; 14: 134.
15. Huang ST, Shu KH, Cheng CH, Wu MJ, Yu TM, Chuang YW, et al. Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients. Transplant Proc 2012; 44: 621-624.
16. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Neprol Dial Transplant 2010; 25: 1183-1191.
17. Liabeuf S, Glorieux G, Lenglet A, Diouf M, Schepers E, Desjardins L, et al. Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? PLoS One 2013; 8: e67168, doi:10.1371/journal.pone.0067168.
18. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558.
19. Lowenstein J. The anglerfish and uremic toxins. FASEB J 2011; 25: 1781-1785.
20. Fricke WF, Maddox C, Song Y, Bromberg JS. Human microbiota characterization in the course of renal transplantation. Am J Transplant 2014; 14: 416-427.
21. Lee JR, Muthukumar T, Dadhania D, Toussaint NC, Ling L, Pamer E, et al. Gut microbial community structure and complications after kidney transplantation: A pilot study. Transplantation 2014; 98: 697-705.
22. Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: Loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 640-645.
23. Burchell B, Coughtrie MW. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect 1997; 105(Suppl 4): 739-747.
24. Saigo C, Nomura Y, Yamamoto Y, Sagata M, Matsunaga R, Jono H, et al. Meclofenamate elicits a nephropreventing effect in a rat model of ischemic acute kidney injury by suppressing indoxyl sulfate production and restoring renal organic anion transporters. Drug Des Dev Ther 2014; 8: 1073-1082.
25. Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, et al. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute [corrected] renal failure. Kidney Int 2007; 71: 539-547.
26. Liu S, Wang BH, Kompa AR, Lekawanvijit S, Krum H. Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. Int J Cardiol 2012; 158: 457-458.
27. Kusumoto M, Kamobayashi H, Sato D, Komori M, Yoshimura M, Hamada A, et al. Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats. Clin Exp Nephrol 2011; 15: 820-830.
28. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31: 1771-1779.